Literature DB >> 26961779

Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics.

J Jaime Caro1,2,3.   

Abstract

Several decision-analytic modeling techniques are in use for pharmacoeconomic analyses. Discretely integrated condition event (DICE) simulation is proposed as a unifying approach that has been deliberately designed to meet the modeling requirements in a straightforward transparent way, without forcing assumptions (e.g., only one transition per cycle) or unnecessary complexity. At the core of DICE are conditions that represent aspects that persist over time. They have levels that can change and many may coexist. Events reflect instantaneous occurrences that may modify some conditions or the timing of other events. The conditions are discretely integrated with events by updating their levels at those times. Profiles of determinant values allow for differences among patients in the predictors of the disease course. Any number of valuations (e.g., utility, cost, willingness-to-pay) of conditions and events can be applied concurrently in a single run. A DICE model is conveniently specified in a series of tables that follow a consistent format and the simulation can be implemented fully in MS Excel, facilitating review and validation. DICE incorporates both state-transition (Markov) models and non-resource-constrained discrete event simulation in a single formulation; it can be executed as a cohort or a microsimulation; and deterministically or stochastically.

Entities:  

Mesh:

Year:  2016        PMID: 26961779     DOI: 10.1007/s40273-016-0394-z

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  12 in total

Review 1.  Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science.

Authors:  E McIntosh; C Donaldson; M Ryan
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

2.  The decision rules of cost-effectiveness analysis.

Authors:  G Karlsson; M Johannesson
Journal:  Pharmacoeconomics       Date:  1996-02       Impact factor: 4.981

Review 3.  Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide.

Authors:  James E Stahl
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.

Authors:  Andrew H Briggs; Milton C Weinstein; Elisabeth A L Fenwick; Jonathan Karnon; Mark J Sculpher; A David Paltiel
Journal:  Value Health       Date:  2012 Sep-Oct       Impact factor: 5.725

5.  Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.

Authors:  David M Eddy; William Hollingworth; J Jaime Caro; Joel Tsevat; Kathryn M McDonald; John B Wong
Journal:  Value Health       Date:  2012 Sep-Oct       Impact factor: 5.725

6.  Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.

Authors:  Sean D Sullivan; Josephine A Mauskopf; Federico Augustovski; J Jaime Caro; Karen M Lee; Mark Minchin; Ewa Orlewska; Pete Penna; Jose-Manuel Rodriguez Barrios; Wen-Yi Shau
Journal:  Value Health       Date:  2013-12-13       Impact factor: 5.725

Review 7.  Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example.

Authors:  U Rochau; B Jahn; V Qerimi; E A Burger; C Kurzthaler; M Kluibenschaedl; E Willenbacher; G Gastl; W Willenbacher; U Siebert
Journal:  Crit Rev Oncol Hematol       Date:  2014-12-31       Impact factor: 6.312

8.  The trade-off between severity of illness and treatment effect in cost-value analysis of health care.

Authors:  E Nord
Journal:  Health Policy       Date:  1993-08       Impact factor: 2.980

9.  Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2.

Authors:  Mark Roberts; Louise B Russell; A David Paltiel; Michael Chambers; Phil McEwan; Murray Krahn
Journal:  Value Health       Date:  2012 Sep-Oct       Impact factor: 5.725

10.  Cost-utility analysis.

Authors:  R Robinson
Journal:  BMJ       Date:  1993-10-02
View more
  19 in total

1.  Good Pharmacovigilance Practice in Paediatrics: An Overview of the Updated European Medicines Agency Guidelines.

Authors:  Janet Sultana; Cosimo Zaccaria; Roberto de Lisa; Francesco Rossi; Annalisa Capuano; Carmen Ferrajolo
Journal:  Paediatr Drugs       Date:  2019-10       Impact factor: 3.022

Review 2.  Overview and Use of Tools for Selecting Modelling Techniques in Health Economic Studies.

Authors:  Huajie Jin; Stewart Robinson; Wenru Shang; Evanthia Achilla; David Aceituno; Sarah Byford
Journal:  Pharmacoeconomics       Date:  2021-05-20       Impact factor: 4.981

3.  Validation of a DICE Simulation Against a Discrete Event Simulation Implemented Entirely in Code.

Authors:  Jörgen Möller; Sarah Davis; Matt Stevenson; J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2017-10       Impact factor: 4.981

4.  Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations.

Authors:  Luis Hernandez; Malinda O'Donnell; Maarten Postma
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

5.  Response to Letter to the Editor Regarding Discretely Integrated Condition Event Simulation for Pharmacoeconomics.

Authors:  J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

6.  Discretely Integrated Condition Event Simulation for Pharmacoeconomics.

Authors:  Mondher Toumi; Ekkehard Beck; Steve Sherman; Leyla Mohseninejad; Samuel Aballéa
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

7.  Smoking Cessation: A Comparison of Two Model Structures.

Authors:  Becky Pennington; Alex Filby; Lesley Owen; Matthew Taylor
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.981

8.  Cooking Up a Transparent Model Following a DICE Recipe.

Authors:  Jörgen Möller
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

9.  A Multidimensional Array Representation of State-Transition Model Dynamics.

Authors:  Eline M Krijkamp; Fernando Alarid-Escudero; Eva A Enns; Petros Pechlivanoglou; M G Myriam Hunink; Alan Yang; Hawre J Jalal
Journal:  Med Decis Making       Date:  2020-01-28       Impact factor: 2.583

10.  Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia.

Authors:  Anuraag R Kansal; Odette S Reifsnider; Sarah B Brand; Neil Hawkins; Anna Coughlan; Shujun Li; Lael Cragin; Clark Paramore; Andrew C Dietz; J Jaime Caro
Journal:  J Mark Access Health Policy       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.